BTCY

Biotricity has a genuinely improving operating story: FY2025 revenue of $13.8M (+14.3% YoY) caps a four-year climb from $3.38M in FY2021, gross margin is a healthy 76.6%, and the net loss has narrowed every year (-$29.1M → -$8.42M). Operating loss shrank 72.3% to -$2.45M and operating cash burn improved 64.4% to -$2.38M. The insourcing, utilization-based recurring-fee model around FDA-cleared Bioflux/Biocore is scaling across 31 states. At a 0.3x P/S the top line looks superficially cheap. But the equity is not a claim on that business — it is a residual claim behind a wrecked balance sheet.

The balance sheet is the whole story and it is dire. Total liabilities of $35.7M tower over $5.64M of assets, leaving stockholders' equity at -$32.0M (liabilities/equity -1.11x) and an accumulated deficit of $139M — the 10-K states $138,895,913 as of March 31, 2025. Cash is just $365K and fell 53.5% in the year, against ~$2.4M of annual operating burn: months of runway, not years. Current liabilities of $20.6M dwarf current assets of $4.64M, a ~$16M working-capital deficit. The MD&A concedes the company 'cannot definitely predict when we will achieve profitability, if ever' and that inability to profit 'may force us to curtail or temporarily discontinue' operations — going-concern language in substance.